Home > Back to Publisher > Report Information

Achieving Success In The Developing Asian Pharmaceutical Sector 2007-2011

Visiongain
November 9, 2006
139 Pages - SKU: VSG1397534

Abstract Table of Contents Related Reports

Countries covered: Asia

Will the economic growth in new Asian markets allow you to offset global problems? With the Japan market slow and stagnant what other countries in the region offer you the greatest opportunities and how can you succeed in them. This report tells you.

Asian Developing Markets for Pharmaceuticals, 2006-2011 delivers to you unique prospects for the largest developing pharmaceutical market - Asia.

This report predicts that all the leading developing markets will exhibit strong growth from 2006-2011. Rapid economic growth and large, under-served populations will drive that expansion in pharmaceutical revenues. There will be significant growth in sales of both branded and generic drugs through increasing demand from both public and private healthcare sectors.

This unique report concentrates on the following themes:

Forecasts of sales revenues and growth rates for leading developing markets in Asia, from 2006-2011
Drivers and opportunities in the markets you should be working in
Restraints and threats in those markets
Discussion of key players and important therapeutic areas
Discussion of relevant regulatory, societal and economic issues
Comparison of the prospects for revenuegeneration in Asia, Latin America and
Central/Eastern Europe, with overall forecasts for those regions
Who you should be working with and why

Why you should buy this report:

To receive a comprehensive analysis of the prospects for developing regional and national markets for pharmaceuticals in Asia from 2006-2011, as well as comparative data for other developing regions
To discover predicted revenues, growth rates and other key metrics for Asian developing markets from 2006-2011
To determine the forces that influence pharmaceutical sales in the Asian developing markets:
Competitive characteristics of the market, both at - national and regional level

Regulatory, technological, societal and political issues
Drivers and restraints
Strengths, weaknesses, opportunities and threats

The dominant pharmaceutical markets of North America, Western Europe and Japan currently account for approximately 85% of revenues for prescription drugs. However, there is concern about the relatively low growth of those established markets in recent years. Consequently, international pharmaceutical companies are very interested in raising their profile in the developing markets of Asia.

You cannot afford to ignore this expanding market. A small investment today will be the catalyst of a great return for your company tomorrow.

Unique benefits to you when you order this report

Full searchable report when you buy the company or corporate editions
Immediate access through our exclusive Reading Room
You can access your report whichever country you are in without using harddrive space
Primary research throughout. You will not find this information anywhere else
Report stored in your reading room for ever
Copies can be printed off for offline reading
Packed with charts, analysis, figures, graphs and tables

If you buy one report this year make sure it is the report that will guarantee your success for the next few years. Order this report now.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Additional Information

Organisations Listed:

Abbott Laboratories
Abdi Ibrahim
Ablomed
Actavis
Adamed
Akrikhin
Alkem
Alpharma
Apex International Clinical Research
Armstrong
AstraZeneca
Bagó
Barr Pharmaceuticals
Bayer
Berlin-Chemie
Bristol-Myers Squibb
Bryntsalov A
Cadila Healthcare
Choong Wae
Cipla
Dae Woong
Dexa Medica
Dong A
Dr Reddy’s Laboratories
Eczacibasi
Egis
Elea
Eli Lilly
F. Hoffman-La Roche
Fresenius
Gador
Gedeon Richter
Genovate Biotec
Geven
GlaxoSmithKline
Guangzhou Tainxin
Han Mi
Heilongjiang Haerbin Pharmaceutical
Hexal
Hoechst Marion Roussel
ICON
II Dong
Immunopreparat
Interbat
Ivax Pharmaceuticals
Jiangsu Lianyungang Hengrui
Johnson & Johnson
Kalbe Farma
Krka
KRKA D.D.
Lek
Menarini
Merck & Co
Merck KGaA
Merck Sharp Dohme
Moskhimpharmpreparaty
MSD Korea
Mylan Laboratories
Nicholas Piramal
Nizpharm
Novartis
Novo Nordisk
Nycomed
Omnicare CR
Otechestvennye Lekarstiva
Otsuka Pharmaceutical
Pascual Laboratories
Perlican
Pfizer
PHARM-CENTR
Pharmstandart
Phoenix
Pliva
Polfa Kutno
Polfa Warszawa
Polpharma SA
Protech Pharmaservice
Quintiles
Ranbaxy Laboratories
Roche
Roemmers
Sanbe Farma
Sandoz
Sanofi-Aventis
Schering Plough
Schwarz Pharmaceutical
Servier Pharmaceuticals
Siam Pharma
Soul-Pattinson
Sun Pharmaceutical Industries
Teva Pharmaceutical
Trans-India Acquisition Corporation
Unichem
United Laboratories
Veropharm
Virginia CRO
VIRION
Watson Pharmaceuticals
Wockhardt
Wyeth
Yangzijiang Pharmaceutical
Yuhan Company
Yung Shin Pharmaceutical Industries
Zentiva
Zydus Cadila

1. Executive Summary: Asian Developing Markets for Pharmaceuticals, 2006-2011
2. The Global Pharmaceutical Industry Faces Significant Challenges - Will Expansion into Developing Markets Prove to Be the Answer?: 2.1 The World Pharmaceutical Market Continues to Grow at a Moderate Rate; 2.2 The Principal Markets Are the US, Japan and Leading EU Economies - But Leading Developing Nations Are Narrowing the Gap in Pharmaceutical Revenues; 2.3 China is the Ninth Largest World Pharmaceutical Market; 2.4 North America, Europe and Japan Continue to Dominate the World Pharmaceutical Market, But Sales in the Developing Markets Are Increasing More Rapidly; 2.5 High Growth in the Developing Markets; 2.6 China is a Most Exciting Prospect for the Pharmaceutical Industry; 2.7 Latin America Exhibits Great Promise for Growth of Pharmaceutical Revenues; 2.8 WTO Agreements Affect Pharmaceutical Developments In Emerging Markets; 2.9 The Continuing Success of the Pharmaceutical Industry is Dependent Upon Important Drivers and Restraints; 2.10 Pharmaceutical Companies Will Jostle Vigorously for Position in Developing Markets; 2.11 The Pharmaceutical Sector Is Gradually Changing Its Strategic Focus to Overcome Challenges in the Market; 2.12 Sales of Generic Products Continue to Encroach Upon the Market for Branded Drugs; 2.13 Patent Protection Strategies Form a Cornerstone of Lifecycle Management; 2.14 Is Innovation Declining in the Pharmaceutical Industry?; 2.15 There Are Strong Forces Acting on Pharmaceutical Pricing In Leading Markets - The Industry Is Under Pressure; 2.16 Maximising the Impact of Product Launches Yields Commercial Advantages; 2.17 Strong Branding is Vital - Both in Established and Emerging Markets; 2.18 Expansion Into Developing Countries Will Help to Reinvigorate The Pharmaceutical Industry from 2006-2011
3. The Chinese Pharmaceutical Market: 3.1 The Chinese Market for Pharmaceuticals Will Expand to $25bn in 2011; 3.2 Growth in National and Personal Prosperity Will Raise Demand for Pharmaceutical Products in China; 3.3 Remaining Concerns About the Commercial Environment in China Will Act As a Restraint to Market Growth; 3.4 The Pharmaceutical Market in China Will be Driven by the Especially Strong Performance of the Chinese Economy from 2005 to 2011; 3.5 The State Food and Drug Administration is The Main Pharmaceutical Regulator in China; 3.6 Western Medicine is Gradually Superseding Traditional Medications in China; 3.7 Yangzijiang Pharmaceutical Was the Market Leader in 2005 With International Pharmaceutical Leaders Also Performing Well; 3.8 Mandatory Pricing Reductions Cause Some Concerns to the Industry; 3.9 The Centralised Tendering System Has an Effect on Pharmaceutical Revenues; 3.10 Counterfeiting and the Violation of Patents Are Still Problematical In China; 3.11 That China is The Largest and Most Attractive Developing Market
4. The Indian Pharmaceutical Market: 4.1 The Indian Pharmaceutical Market Will Expand Rapidly from 2005-2011; 4.2 The Indian Pharmaceutical Market Will Benefit from Many Important Drivers; 4.3 Potential for Growth In the Indian Market Is Exciting, But Poverty and Lack of Developments Remain Serious Hurdles; 4.4 India Is the Second Fastest Growing Major Economy After China; 4.5 Political And Economic Reforms Have Eased India’s Transition into the Modern, Globalised Economy; 4.6 Widespread Poverty Remains a Major Problem in India - There is a Vast Potential Market for Pharmaceuticals But Usually Only Limited Resources for Purchasing Branded Drugs; 4.7 India Has an Expanding Professional Class Which Serves As a Strong Driver of Growth in The Pharmaceutical Market; 4.8 Domestic Companies Generated 75% of Sales in the Indian Pharmaceutical Market in 2005; 4.9 State Governments Are Responsible for Providing Healthcare - However Patients Are Very Reliant on The Private Sector; 4.10 India Currently Has A Fragmented Procedure for Drug Approval - The Establishment of a National Drugs Agency Should Rationalise the Process; 4.11 India Is a Highly Attractive Location for R&D Activities; 4.12 The Indian Pharmaceutical Market: Conclusions
5. Other Developing Pharmaceutical Markets in Asia: 5.1 Asia Constitutes the World’s Largest Developing Market for Pharmaceuticals, With Immense Potential for Growth from 2005 to 2011; 5.2 Developing Asian Pharmaceutical Markets Have Important Advantages for Companies; 5.3 Low Per Capita Healthcare Spending Constitutes the Most Significant Restraint to the Asian Pharmaceutical Market; 5.4 It is Not Yet Clear How Well Public and Private Initiatives Will Raise Standards of Healthcare Consistently in Asia; 5.5 Prices in Asia Face Increasing Pressure from Governmental Controls and Market Forces; 5.6 Protection of IP is a Key Concern in Asia; 5.7 Markets for Generics Will Show Continuing Growth as Asian Markets Depend Heavily on Basic Drugs; 5.8 The Asian Market Will Be Strongly Driven by Growth in Key Therapeutic Categories; 5.9 The Pharmaceutical Market in South Korea; 5.10 The Pharmaceutical Market in Turkey; 5.11 The Pharmaceutical Market in Taiwan; 5.12 The Pharmaceutical Market in Indonesia; 5.13 The Pharmaceutical Market in the Philippines; 5.14 The Pharmaceutical Market in Thailand; 5.15 Overview of Developing Pharmaceutical Markets in Asia
6. Conclusions: 6.1 China Will Produce the Largest Revenues of All the Developing Pharmaceutical Markets As Well As the Highest Growth Rate; 6.2 Overall Growth of the Leading Developing Markets from 2005-2011 Will Be More than Twice that of the Global Pharmaceutical Market; 6.3 The Leading Developing Markets Combined Will Generate More Than a Sixth of Global Pharmaceutical Revenues in 2011; 6.4 The Main Drivers of Developing Markets Will Be Increasing Prosperity and High Un-met Needs for Modern Treatments; 6.5 The Main Restraint to Growth Will Be Continuing Poverty in the Developing World
List of Tables: Table 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005; Table 2.2 Forecast Revenue Generation ($bn) by the World Pharmaceutical Market, 2005-2011; Table 2.3 Top 20 Ranking Nations in the Global Pharmaceutical Market, 2005; Table 2.4 How the Top 10 Markets Compared With The Rest of the World, 2005; Table 2.5 World Pharmaceutical Revenues ($bn) by Region, 2005; Table 2.6 Revenues ($bn), Growth (%) and Market Share (%) for Leading Developing Markets, 2005; Table 2.7 Combined Revenues ($bn), Growth (%) and Market Share (%) for Leading Developing Markets by Region, 2005; Table 2.8 A SWOT Analysis for Developing Pharmaceutical Markets, 2006-2011; Table 2.9 The 10 Most Populous Countries - 2005 and 2030 Compared; Table 3.1 Pharmaceutical Revenues ($bn) for China, 2005-2011; Table 3.2 China: Fundamental Demographics and Healthcare Economics; Table 4.1 Pharmaceutical Revenues ($bn) for India, 2005-2011; Table 4.2 India: Fundamental Demographics and Healthcare Economics; Table 5.1 Revenues ($bn) for Leading Markets in Asia, 2005-2011; Table 5.2 Pharmaceutical Revenues ($bn) for South Korea, 2005-2011; Table 5.3 South Korea: Fundamental Demographics and Healthcare Economics; Table 5.4 Pharmaceutical Revenues ($bn) for Turkey, 2005-2011; Table 5.5 Turkey: Fundamental Demographics and Healthcare Economics; Table 5.6 Pharmaceutical Revenues ($bn) for Taiwan, 2005-2011; Table 5.7 Taiwan: Fundamental Demographics and Healthcare Economics; Table 5.8 Pharmaceutical Revenues ($bn) for Indonesia, 2005-2011; Table 5.9 Indonesia: Fundamental Demographics and Healthcare Economics; Table 5.10 Pharmaceutical Revenues ($bn) for the Philippines, 2005-2011; Table 5.11 Philippines: Fundamental Demographics and Healthcare Economics; Table 5.12 Pharmaceutical Revenues ($bn) for Thailand, 2005-2011; Table 5.13 Thailand: Fundamental Demographics and Healthcare Economics; Table 6.1 The Leading Developing Markets Ranked in Order of Potential Revenue Generation ($bn), 2011; Table 6.2 Developing Markets Ranked by Growth Rate (CAGR %), 2005-2011; Table 6.3 Revenues ($bn) for Leading Developing Markets by Region, 2005-2011; Table 6.4 Share (%) of the World Market by Developing Region, 2005-2011
List of Figures: Figure 2.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005; Figure 2.2 Forecast Revenue Generation ($bn) by the World Pharmaceutical Market, 2005-2011; Figure 2.3 World Pharmaceutical Revenues ($bn) by Region, 2005; Figure 2.4 World Market Share (%) by Region, 2005; Figure 2.5 Growth Rates (%) from Previous Year by Region, 2005; Figure 2.6 The Increasing Average Cost ($m) of NME Development, 1976-2005; Figure 3.1 Pharmaceutical Revenues ($bn) for China, 2005-2011; Figure 3.2 World Market Share (%) for China - 2005 and 2011 Compared; Figure 3.3 Breakdown (%) of the Chinese Market ($bn) by Conventional Prescription Drugs, OTC Products and Traditional Chinese Medicines, 2005; Figure 3.4 Estimated Revenues of Leading Companies in the Chinese Pharmaceutical Market, 2005; Figure 3.5 Leading Therapeutic Areas ($m) In the Chinese Pharmaceutical Market, 2005; Figure 4.1 Pharmaceutical Revenues ($bn) for India, 2005-2011; Figure 4.2 World Market Share (%) for India - 2005 and 2011 Compared; Figure 4.3 Breakdown (%) of India's GDP by Sector, 2005; Figure 4.4 Sales of Leading Companies in the Indian Market, 2004; Figure 4.5 Leading Therapeutic Areas ($m) In the Indian Pharmaceutical Market, 2005; Figure 4.6 A Breakdown (%) of the Indian Government's Budget for Healthcare, 2006-2007; Figure 5.1a Revenues ($bn) for Leading Markets in Asia, 2005-2011; Figure 5.1b Revenues ($bn) for Leading Markets in Asia, 2005-2011; Figure 5.2 Combined Revenues ($bn) for Leading Markets in Asia, 2005-2011; Figure 5.3 Growth Rates (% CAGR) for the Asian Developing Markets, 2005-2011; Figure 5.4 Pharmaceutical Revenues ($bn) for South Korea, 2005-2011; Figure 5.5 World Market Share (%) for South Korea - 2005 and 2011 Compared; Figure 5.6 Pharmaceutical Revenues ($bn) for Turkey, 2005-2011; Figure 5.7 World Market Share (%) for Turkey - 2005 and 2011 Compared; Figure 5.8 Pharmaceutical Revenues ($bn) for Taiwan, 2005-2011; Figure 5.9 World Market Share (%) for Taiwan - 2005 and 2011 Compared; Figure 5.10 Pharmaceutical Revenues ($bn) for Indonesia, 2005-2011; Figure 5.11 World Market Share (%) for Indonesia - 2005 and 2011 Compared; Figure 5.12 Pharmaceutical Revenues ($bn) for the Philippines, 2005-2011; Figure 5.13 World Market Share (%) for the Philippines - 2005 and 2011 Compared; Figure 5.14 Pharmaceutical Revenues ($bn) for Thailand, 2005-2011; Figure 5.15 World Market Share (%) for Thailand - 2005 and 2011 Compared; Figure 6.1 Revenues ($bn) for Leading Developing Markets by Region, 2005-2011; Figure 6.2 Revenues ($bn) for Leading Markets of Developing Regions Combined, 2005-2011; Figure 6.3 Share (%) of the World Market by Developing Region, 2005-2011; Figure 6.4 Share (%) of the World Market by Developing Regions Combined, 2005-2011

More Asia Prescription Drugs Reports

Japan Pharma Market Intelligence by PharmaIntellect
Looking at the great deal of business interest in the Japan Pharmaceutical space, we have recently published a report - "Japan Pharma – Market ...

China's Pharmaceutical Industry 2011 by China Research and Intelligence Co., Ltd.
This report describes the general development of China’s pharmaceutical industry in aspects of investment, production, sales, import & export, major prices and operations. ...

Anti-Infective Pharmaceuticals Market in India 2012 by Netscribes (India) Pvt. Ltd.
Anti-infective pharmaceuticals market in India is the largest contributor to domestic pharmaceutical sales, contributing around 18%. Since India has a huge patient pool, the Indian ...

Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program by GBI Research
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program Summary GBI Research, the leading business ...

India Pharmaceutical Industry Research and Forecast to 2016 by AM Mindpower Solutions
EXECUTIVE SUMMARY The report titled “India Pharmaceutical Industry Research and Forecast to 2016” offer detailed analysis on the country’s bulk and formulations market which is sub-segmented ...

See all reports like this >>

More Asia Reports

D&B Country RiskLine Report: Vietnam by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country RiskLine Report: Uzbekistan by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country RiskLine Report: Turkmenistan by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country RiskLine Report: Turkey by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country RiskLine Report: Thailand by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

See all reports like this >>

Achieving Success In The Developing Asian Pharmaceutical Sector 2007-2011

Share this report

Other tasks

Research Assistance

Related Markets

Prescription Drugs Reports

Free Alert Me service